INTEGRA Biosciences has acquired Miroculus, a biotechnology specialist focused on developing hands-off automation solutions for next generation sequencing (NGS) protocols.
The acquisition will allow INTEGRA to expand its product range for library preparation, offering significant time savings to academic, research and diagnostics laboratories using NGS and, ultimately, accelerating discovery in this dynamic field.
Miroculus is based in San Francisco, California, and was founded to develop innovative and intuitive tools that simplify complex genomics protocols, making them accessible to a wider range of scientists. Pictured are Miroculus team members welcome new colleagues from INTEGRA to the Miroculus office in San Francisco.
Urs Hartmann, CEO of INTEGRA, said: “We have acquired this promising start-up because we recognise the huge potential of its revolutionary digital microfluidics technology for automating and miniaturising genomics protocols. Miroculus’ proprietary platform delivers assay flexibility and automation capacity, which enables seamless workflow integration, streamlining the experimental process and empowering researchers to translate their discoveries into practical solutions that will improve people’s lives.”
INTEGRA acquired Miroculus in order to better serve the growing NGS market with novel and precise solutions for applications such as automating long-read sequencing and target enrichment protocols. The acquisition also ensures ongoing company growth and safeguards staff; high priorities for both companies.
Visit the INTEGRA Biosciences website to learn more - www.integra-biosciences.com.
